Local and systemic immune responses during rhBMP-2 mediated bone regeneration are dose-dependent in rat model of critical-sized bone defect healing
Bone · 2026
DOI: 10.1016/j.bone.2026.118084 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bone, 2026. Verfasst von Lia K Strait und 9 weiteren Autor:innen. Beteiligte Einrichtung: Phil and Penny Knight Campus for Accelerating Scientific Impact, University of Oregon, Department of Bioengineering, Eugene, OR, USA. Electronic addr…. Hauptthemen laut MEDLINE: Bone Morphogenetic Protein 2, Bone Regeneration, Wound Healing. Die Arbeit nennt 57 Literaturangaben. Gefördert von: NIAMS NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Bone morphogenetic proteins (BMPs) are among the most potent clinical therapeutics for promoting bone regeneration, yet their use is limited by potential adverse events such as heterotopic bone formation, osteolysis, and soft tissue inflammation. Sustained release delivery systems may reduce the minimum effective BMP dose needed to induce functional bone healing but have yet to be fully characterized or translated to clinical use. Here, we utilized a rat model of segmental femur defect healing to investigate the dose-dependent inflammatory effects of BMP delivery in a hydrogel-based system by profiling local and systemic immune responses. Defects were treated with the delivery vehicle only (control), a minimum effective dose of BMP-2, or a high dose of BMP-2. The minimum effective BMP-2 dose induced comparable bone formation within the defects but significantly less ossification outside the defect region relative to the high dose. Immune profiling revealed significant dose-dependent effects of BMP-2 delivery on cellular and proteomic signatures both locally and systemically. Notably, however, no significant differences in immune response markers were detected between the vehicle only control and minimum effective dose groups at any timepoint. This study confirms that BMP-2 delivered at high doses incites strong inflammatory responses locally and systemically, but sustained delivery of a minimum effective dose can regenerate bone without provoking bone formation outside the intended delivery location or inflammatory side effects. The results of this study are limited to only two BMP-2 doses and a sustained-release delivery system, and may not remain true in the FDA-approved collagen sponge.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Phil and Penny Knight Campus for Accelerating Scientific Impact, University of Oregon, Department of Bioengineering, Eugene, OR, USA. Electronic address: lstrait2@uoregon.edu.
- Phil and Penny Knight Campus for Accelerating Scientific Impact, University of Oregon, Department of Bioengineering, Eugene, OR, USA.
- School of Medicine, Oregon Health & Science University, Department of Orthopaedics and Rehabilitation, Portland, OR, USA.
Förderung
- NIAMS NIH HHS
- National Institutes of Health
Zitieren
APA
Strait, L. K., Rose, L., Guyer, T., Jones, K. A., DeKeyser, G. J., Link, K., Gill, D., Hajarizadeh, A., Leguineche, K. E., & Guldberg, R. E. (2026). Local and systemic immune responses during rhBMP-2 mediated bone regeneration are dose-dependent in rat model of critical-sized bone defect healing. Bone. https://doi.org/10.1016/j.bone.2026.118084
Vancouver
Strait LK, Rose L, Guyer T, Jones KA, DeKeyser GJ, Link K, et al. Local and systemic immune responses during rhBMP-2 mediated bone regeneration are dose-dependent in rat model of critical-sized bone defect healing. Bone. 2026. doi:10.1016/j.bone.2026.118084
BibTeX
@article{Strait2026,
author = {Strait, Lia K and Rose, Lucy and Guyer, Tyler and Jones, Kimberly A and DeKeyser, Graham J and Link, Kaitlyn and Gill, Dylan and Hajarizadeh, Auveen and Leguineche, Kelly E and Guldberg, Robert E},
title = {Local and systemic immune responses during rhBMP-2 mediated bone regeneration are dose-dependent in rat model of critical-sized bone defect healing},
journal = {Bone},
year = {2026},
doi = {10.1016/j.bone.2026.118084}
}
EUVIMED